Deoxy-D-Glucose an adjuvant therapy
- July 10, 2021
- Posted by: OptimizeIAS Team
- Category: DPN Topics
No Comments
Deoxy-D-Glucose an adjuvant therapy
Subject: Science and Technology
Context: UR BUREAU Hyderabad, MSN Laboratories has entered into a license agreement with Defence Research & Development Establishment (DRDE) and Institute of Nuclear Medicine and Allied Sciences (INMAS) establishments of the Defence Research & Development Organization (DRDO) for the manufacturing, distribution and marketing of 2- Deoxy-D-Glucose (2-DG) in India.
Concept:
The 2-DG as a twice-a-day product in sachet form under the brand name MSN 2D, in strength of 2.34g.
- It was developed by DRDO, has been granted permission by Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe Covid-19 patients.
Adjuvant therapy
- Adjuvant therapy, also known as adjunct therapy, and adjuvant care, is therapy that is given in addition to the primary or initial therapy to maximize its effectiveness
- The surgeries and complex treatment regimens used in cancer therapy have led the term to be used mainly to describe adjuvant cancer treatments.
- The additional treatment usually given after surgery where all detectable disease has been removed, but where there remains a statistical risk of relapse due to the presence of undetected disease. If known disease is left behind following surgery, then further treatment is not technically adjuvant.
- An adjuvant used on its own specifically refers to an agent that improves the effect of a vaccine. Medications used to help primary medications are known as add-ons.
- For example, radiotherapy or systemic therapy is commonly given as adjuvant treatment after surgery for breast cancer. Systemic therapy consists of chemotherapy, immunotherapy or biological response modifiers or hormone therapy.
- The aim of adjuvant treatment is to improve disease-specific symptoms and overall survival. Because the treatment is essentially for a risk, rather than for provable disease, it is accepted that a proportion of patients who receive adjuvant therapy will already have been cured by their primary surgery